Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) but lowers the price target from $50 to $44.

February 27, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Day One Biopharmaceutical but lowers the price target from $50 to $44.
While the reduction in price target from $50 to $44 by Goldman Sachs could suggest a reassessment of the company's near-term prospects, the maintenance of a Buy rating indicates a continued positive outlook on the company's long-term potential. This mixed signal could lead to short-term price volatility as investors digest the implications of the revised price target against the backdrop of an overall positive recommendation.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100